Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Thescientificworldjournal|May 6, 2008
Advances in the renin-angiotensin-aldosterone system: relevance to diabetic nephropathyAudrey Koitka, Christos Tikellis
IEEE Transactions on Bio-Medical Engineering|November 27, 2002
Wavelet de-noising of laser Doppler reactive hyperemia signals to diagnose peripheral arterial occlusive diseasesAnne Humeau, Audrey Koitka, Jean-Louis Saumet, et al.
Journal of Hypertension|April 22, 2009
Eplerenone does not attenuate diabetes-associated atherosclerosisPhilip J W Koh, Audrey Koitka, Mark E Cooper, et al.
Journal of Diabetes Investigation|November 10, 2018
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trialTakashi Kadowaki, Masaomi Nangaku, Stefan Hantel, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2017
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trialDavid Z I Cherney, Bernard Zinman, Silvio E Inzucchi, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 30, 2020
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational TrialAdeera Levin, Vlado Perkovic, David C Wheeler, et al.
Diabetes|January 26, 2019
Neurovascular Response to Pressure in Patients With Diabetic Foot UlcerJulien Vouillarmet, Audrey Josset-Lamaugarny, Paul Michon, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 10, 2019
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trialVlado Perkovic, Audrey Koitka-Weber, Mark E Cooper, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trialChristoph Wanner, Silvio E Inzucchi, Bernard Zinman, et al.
Journal of Hypertension|December 13, 2018
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuriaMark E Cooper, Vlado Perkovic, Per-Henrik Groop, et al.
Pageof 3